Blueprint Medicines (NASDAQ:BPMC) Lifted to “Strong-Buy” at Baird R W
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. BPMC has been the topic of a number of other reports. Barclays upped their price target on Blueprint Medicines from $75.00 to […]
More Stories
Chenghe Acquisition I Co. Shareholders Approve Business Combination Agreement and Name Change
Chenghe Acquisition I Co. (NASDAQ: LATGU) recently held an extraordinary general meeting where important decisions were made by shareholders. The...
**bioAffinity Technologies Reports Results of 2024 Special Meeting**
bioAffinity Technologies, Inc. (NASDAQ: BIAF) recently held its 2024 Special Meeting of Stockholders on December 20, 2024, where pivotal decisions...
Kirkland’s Target of Unusually High Options Trading (NASDAQ:KIRK)
Kirkland’s, Inc. (NASDAQ:KIRK – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders acquired...
Stock Traders Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors...
B. Riley Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $13.00
OptimizeRx (NASDAQ:OPRX – Free Report) had its price target decreased by B. Riley from $17.00 to $13.00 in a research...
Broadridge Financial Solutions, Inc. (NYSE:BR) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Broadridge Financial Solutions, Inc. (NYSE:BR – Get Free Report) have received a consensus recommendation of “Hold” from the...